Business Description
Harbin Pharmaceutical Group Co Ltd
NAICS : 325412
ISIN : CNE0000009T3
Share Class Description:
SHSE:600664: Class ACompare
Compare
Traded in other countries / regions
600664.China IPO Date
1993-06-29Description
Harbin Pharmaceutical Group Co Ltd is engaged in manufacturing, trading and research and development of pharmaceuticals. The company is organized into seven business segments - Antibiotics, Small-Molecular drug preparations, OTC and healthcare products, Modern Chinese medicines, Biopharmaceuticals, Animal vaccines, and medicine circulations. The company sells its products across China and fifty other countries. Some of its brands are - Hayao, Sanjing, Gaizhonggai, Hutong, and Shiyitang.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.72 | |||||
| Equity-to-Asset | 0.37 | |||||
| Debt-to-Equity | 0.35 | |||||
| Debt-to-EBITDA | 1.94 | |||||
| Interest Coverage | 17.99 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.55 | |||||
| Beneish M-Score | -2.41 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 13.3 | |||||
| 3-Year Book Growth Rate | 10.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 41.07 | |||||
| Future 3-5Y Total Revenue Growth Rate | 8.07 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.68 | |||||
| 9-Day RSI | 53.11 | |||||
| 14-Day RSI | 52.41 | |||||
| 6-1 Month Momentum % | 43.73 | |||||
| 12-1 Month Momentum % | 11.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.35 | |||||
| Quick Ratio | 1.11 | |||||
| Cash Ratio | 0.4 | |||||
| Days Inventory | 59.8 | |||||
| Days Sales Outstanding | 103.84 | |||||
| Days Payable | 120.93 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.2 | |||||
| Shareholder Yield % | 1.3 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 28.4 | |||||
| Operating Margin % | 6.21 | |||||
| Net Margin % | 3.78 | |||||
| FCF Margin % | 1.29 | |||||
| ROE % | 12.51 | |||||
| ROA % | 4.34 | |||||
| ROIC % | 13.2 | |||||
| ROC (Joel Greenblatt) % | 30.64 | |||||
| ROCE % | 15.52 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 16.5 | |||||
| Forward PE Ratio | 13.2 | |||||
| PE Ratio without NRI | 15 | |||||
| Shiller PE Ratio | 32.9 | |||||
| Price-to-Owner-Earnings | 20.2 | |||||
| PS Ratio | 0.62 | |||||
| PB Ratio | 1.91 | |||||
| Price-to-Tangible-Book | 2.12 | |||||
| Price-to-Free-Cash-Flow | 45.52 | |||||
| Price-to-Operating-Cash-Flow | 30 | |||||
| EV-to-EBIT | 10.01 | |||||
| EV-to-EBITDA | 10.01 | |||||
| EV-to-Revenue | 0.58 | |||||
| EV-to-FCF | 44.83 | |||||
| Price-to-Projected-FCF | 2.06 | |||||
| Price-to-Median-PS-Value | 0.74 | |||||
| Price-to-Graham-Number | 1.19 | |||||
| Price-to-Net-Current-Asset-Value | 6.19 | |||||
| Earnings Yield (Greenblatt) % | 9.99 | |||||
| FCF Yield % | 2.1 | |||||
| Forward Rate of Return (Yacktman) % | -20.74 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Harbin Pharmaceutical Group Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 16,219.167 | ||
| EPS (TTM) (Â¥) | 0.24 | ||
| Beta | 0.89 | ||
| Volatility % | 36 | ||
| 14-Day RSI | 52.41 | ||
| 14-Day ATR (Â¥) | 0.119989 | ||
| 20-Day SMA (Â¥) | 3.967 | ||
| 12-1 Month Momentum % | 11.18 | ||
| 52-Week Range (Â¥) | 2.41 - 4.26 | ||
| Shares Outstanding (Mil) | 2,518.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Harbin Pharmaceutical Group Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Harbin Pharmaceutical Group Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Harbin Pharmaceutical Group Co Ltd Frequently Asked Questions
What is Harbin Pharmaceutical Group Co Ltd(SHSE:600664)'s stock price today?
The current price of SHSE:600664 is ¥3.96. The 52 week high of SHSE:600664 is ¥4.26 and 52 week low is ¥2.41.
When is next earnings date of Harbin Pharmaceutical Group Co Ltd(SHSE:600664)?
The next earnings date of Harbin Pharmaceutical Group Co Ltd(SHSE:600664) is .
Does Harbin Pharmaceutical Group Co Ltd(SHSE:600664) pay dividends? If so, how much?
Harbin Pharmaceutical Group Co Ltd(SHSE:600664) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers